26 April 2024 - Breast Cancer Network Australia (BCNA) today welcomed a decision by the PBAC to recommend the life prolonging breast cancer drug Enhertu (trastuzumab deruxtecan) for government subsidy on the Pharmaceutical Benefits Scheme for HER2 low metastatic breast cancer.

However, BCNA Director of Policy, Advocacy & Support Services, Vicki Durston, said that we are not yet able to celebrate because the drug remains out of reach to thousands who need it. This is because the pharmaceutical company AstraZeneca refuses to increase access by lowering the price of its Patient Access Program for Enhertu.

Read Breast Cancer Network Australia press release